Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 4
1999 pubmed

A New Orphan Receptor Involved in Pulsatile Growth Hormone Release.

Smith. RG RG; Feighner. S S; Prendergast. K K; Guan. X X; Howard. A A

Key Findings

  • GHS‑R is the receptor that drives the natural, pulsatile release of growth hormone and is activated by GHRP‑6 and similar synthetic ligands.
  • The receptor’s ligand‑binding pocket has been conserved for ~400 million years, underscoring its fundamental role in metabolism and brain function.
  • Long‑term activation of GHS‑R with a synthetic ligand (MK‑0677) restored age‑related declines in the GH/IGF‑I axis in people aged 70‑94, hinting at possible benefits for cognition, mood, and body composition.

Practical Outcomes

  • For biohackers, using GHRP‑6 (or other GHS‑R agonists) can reliably trigger GH pulses, which may aid muscle growth, fat loss, and recovery. Chronic, low‑dose use could help counteract the natural drop in GH/IGF‑1 that comes with aging, potentially improving cognition and mood as well. However, dosing schedules and long‑term safety still need careful personal experimentation and monitoring.

Summary

Scientists discovered that a special receptor called GHS‑R (the ghrelin or GH secretagogue receptor) is the key switch that makes the pituitary release growth hormone in bursts. This receptor is turned on by the GH‑releasing peptides like GHRP‑6, and activating it can boost the GH/IGF‑1 system, especially in older people where the natural signal fades.

Abstract

In all species studied to date, growth hormone (GH) is released episodically. Traditionally, the regulation of this process was considered to be mediated by two hypothalamic hormones, growth hormone-releasing hormone (GHRH) and somatostatin (sst). More recently, we identified a new orphan G-protein-coupled receptor that causes episodic GH release upon activation by synthetic ligands. These ligands include the GH-releasing peptides (GHRPs) first described by Bowers and their small molecule mimetics such as L-692,429 and MK-0677. Site-directed mutagenesis of this GH secretagogue receptor (GHS-R) has defined key amino acid residues essential for binding and activation by the synthetic ligands. The GHS-R is not activated by GHRH or sst. It is expressed exclusively in the anterior pituitary lobe and central nervous system and although this new receptor does not belong to any of the known families of G-protein-coupled receptors, the GHS-R is highly conserved across species. The Puffer fish homolog, in common with the human GHS-R, is activated by the structurally distinct ligands GHRP-6, MK-0677 and L-163,540. Thus, the GHS-R ligand-binding pocket has apparently been conserved for at least 400 million years. Studies in humans suggest that production of an endogenous ligand declines during aging. For example, chronic treatment with the synthetic ligand MK-0677 reverses the age-related physiological changes in the GH/IGF-I (insulin-like growth factor I) axis of 70-94 year old subjects. Based on the localization of expression of GHS-R in the brain, reduced production of the natural ligand might also be involved in age-associated changes in cognition, memory, mood and behavior.

Study Information

Provider

pubmed

Year

1999

DOI

10.1016/s1043-2760(98)00132-5